Zosano Pharma (ZSAN) – Globe Newswire
-
Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11
-
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
-
Zosano Pharma Reports First Quarter 2022 Financial Results
-
Zosano Pharma Provides Corporate Update
-
Zosano Pharma Announces Reverse Stock Split Effective Today
-
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results
-
Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants
-
Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants
-
CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an In
-
Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular I
-
Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang
-
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System
-
Zosano Pharma Reports Third Quarter 2021 Financial Results
-
Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results
-
Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference
-
Zosano Pharma Reports Second Quarter 2021 Financial Results
-
Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine
-
Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain
-
Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors
-
Zosano Pharma Reports First Quarter 2021 Financial Results
-
Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA
-
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results
-
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Zillow Group and Zosano Pharma and Encourages Investors to Contact the Firm
-
Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference
-
Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA
-
Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines
-
Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA
-
Zosano Pharma Requests Type A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug Application
-
Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference
-
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Zosano Pharma Corp. and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against JPMorgan, First American Financial, BMW, and Zosano Pharma and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
-
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Zosano Pharma Reports Third Quarter 2020 Financial Results
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
-
ZOSANO PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zosano Pharma Corp. on Behalf of Zosano Stockholders and Encourages Investors to Contact the Firm
-
Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta™
-
Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDA
-
Zosano Pharma to Present at the Cantor Virtual Global Healthcare Conference
-
Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference
-
Zosano Announces Pricing of Public Offering of Common Stock
-
Zosano Pharma Announces Proposed Public Offering of Common Stock
-
Zosano Pharma Announces Agreement to Collaborate with Mitsubishi Tanabe Pharma Corporation
-
Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™
-
Zosano Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Back to ZSAN Stock Lookup
